High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Influenza, also known as the flu, is a contagious respiratory illness caused by influenza
viruses. The illness can range in severity, from mild to severe to even death, and it causes
an estimated 500,000 to 1,000,000 deaths worldwide each year. In the last several years,
there have been increasing numbers of human cases of avian influenza, or bird flu. This trend
may pose a threat of a future pandemic--worldwide outbreak of disease--with an avian
influenza virus that can easily spread from person to person. Oseltamivir is an antiviral
medication that is used to treat people with uncomplicated human influenza, and it may be
effective in treating people with either severe human influenza or avian influenza. The
purpose of this international study is to compare standard-dose oseltamivir versus high-dose
oseltamivir for treating people who are hospitalized with severe human influenza or avian
influenza.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
University of Oxford Wellcome Trust World Health Organization